Clinical Edge Journal Scan

Meta-analysis shows geriatric nutritional risk index to be a strong predictor of survival in DLBCL


 

Key clinical point: A low (below cutoff) geriatric nutritional risk index (GNRI) score is significantly associated with worse prognosis in patients with diffuse large B-cell lymphoma (DLBCL).

Major finding: A low GNRI score was significantly associated with worse overall survival (pooled hazard ratio [pHR] 1.78; P < .01) and progression-free survival (pHR 2.31; P < .01).

Study details: This meta-analysis included seven retrospective cohort studies that provided a cutoff value for GNRI (between 92 and 104.24) and involved 2448 patients with DLBCL for whom a calculated GNRI score was available.

Disclosures: This study was supported by Key R&D Projects, Jiangxi. The authors declared no conflicts of interest.

Source: Yan C et al. Prognostic value of geriatric nutritional risk index in patients with diffuse large B-cell lymphoma: A meta-analysis. Clin Transl Oncol. 2023 (Jul 12). doi: 10.1007/s12094-023-03271-w

Recommended Reading

Commentary: BTK inhibition in CLL and MCL, August 2023
B-Cell Lymphoma ICYMI
Final phase 2 results favor acalabrutinib therapy in relapsed or refractory MCL
B-Cell Lymphoma ICYMI
Combination of MIPI, Ki-67, and p53 expression defines a high-risk group in MCL
B-Cell Lymphoma ICYMI
AlloSCT leads to long-term remissions in TP53-mutated MCL
B-Cell Lymphoma ICYMI
Rituximab plus chemotherapy vs chemotherapy alone improves survival in untreated advanced-stage MCL
B-Cell Lymphoma ICYMI
Zanubrutinib and obinutuzumab combo shows promise for relapsed or refractory FL
B-Cell Lymphoma ICYMI
Idelalisib a favorable treatment option for pretreated relapsed or refractory CLL in the absence of alternatives
B-Cell Lymphoma ICYMI
Lenalidomide plus R-ESHAP a feasible salvage regimen in relapsed or refractory DLBCL
B-Cell Lymphoma ICYMI
Bendamustine plus rituximab improves survival over rituximab plus CVP or CHOP in indolent B-cell lymphoma
B-Cell Lymphoma ICYMI
Pre-treatment serum IL-6 and IL-10 levels predict prognosis and treatment response in newly diagnosed DLBCL
B-Cell Lymphoma ICYMI